Moderna shares rose 6% to $239.74 in afternoon trading, far outpacing peers BioNTech (NASDAQ:BNTX), up 2% to $90.10, and Pfizer (NYSE:PFE), up 2% to $29.65. The article links the move to money rotating out of AI and technology stocks into healthcare, with the iShares Biotechnology ETF (NASDAQ:IBB) up 3% to $208.35 while the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) was flat at $769.61. Moderna's outsized gain may also reflect an August late-stage melanoma trial, in which its personalized mRNA cancer vaccine given with Merck's Keytruda beat Keytruda alone. The article says fuller trial data is needed to confirm that story.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Related news
- Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Moderna shares fell 10% to $214.03 in morning trading as investors took profits after a steep rally tied to its personalized cancer vaccine. In August, Moderna said intismeran autogene, given with Keytruda, met its primary endpoint in a late-stage melanoma trial, sending the stock to its best single-day gain ever. Five-year follow-up from a Phase 2b study showed the combination cut the risk of recurrence or death by 49% versus Keytruda alone. Meanwhile, BioNTech fell 2%, Pfizer rose 0.3%, the iShares Biotechnology ETF slid 2% and the S&P 500 ETF (SPY) dipped 0.1%, pointing to selling concentrated in Moderna. Goldman Sachs raised its price target but kept a Neutral rating, with full melanoma data due at ESMO later this month.
- Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?
Moderna's market cap is near $90 billion, about 3.6 times BioNTech's under $25 billion, after the two traded at similar levels for nearly the first eight months of 2026. Moderna's shares have risen more than 660% year to date on Phase 3 results for its personalized mRNA cancer vaccine intismeran autogene combined with Merck's Keytruda in melanoma, while BioNTech halted a Phase 2 colorectal cancer study in August because its vaccine proved ineffective, and co-founders Uğur Şahin and Özlem Türeci plan to leave by the end of 2026. Moderna trades above 32 times sales versus BioNTech's roughly 8 times, and analysts are far more bullish on BioNTech: 11 of 15 recommend buying, compared with only 3 of 20 for Moderna, whose average price target sits 52.5% below its share price. The author agrees BioNTech is the smarter pick at current valuations, citing its cash position of roughly $18.6 billion at the end of Q2.
- Walmart Advances 3% as Inflation Data Sends Money Into Defensives; Costco and Target Edge Higher
A hotter-than-expected September inflation report pushed money into consumer staples while the broader market fell. Walmart (WMT) rose 3% to $115.10, Costco (COST) gained 2% to $976.30, and Target (TGT) edged up 0.9% to $153.43, while the SPDR S&P 500 ETF fell 1.33%. Walmart beat expectations with Q2 FY2027 adjusted EPS of $0.81 and revenue up 5.9% to $187.94 billion, and raised its full-year adjusted EPS guidance to $2.80–$2.87, though the stock trades at a P/E of 41x. Costco reported Q4 FY2026 comparable sales up 9.4%, while Target raised its full-year adjusted EPS guidance to $9.90–$10.90, a range that includes $1.65 per share from tariff refunds. Target shares are up 61% year to date.
- Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady
Novavax (NASDAQ:NVAX) fell 12% to $11.23 in afternoon trading, leading a selloff in vaccine stocks, while Moderna (NASDAQ:MRNA) dropped 10% to $212.80 and Pfizer (NYSE:PFE) rose 0.5% to $29.59. Novavax depends on partner Sanofi, which holds U.S. approval for its Nuvaxovid vaccine and is rolling it out in the UK, Germany and Canada; Novavax earns royalties and milestone payments rather than selling the vaccine itself. Citi kept its Sell rating on Novavax while raising its price target just before the drop. The iShares Biotechnology ETF (NASDAQ:IBB) fell 2% and the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) fell 0.6%, suggesting the heaviest pressure is concentrated in vaccine developers. The article notes royalties could grow as Nuvaxovid reaches more countries, but milestone timing depends on Sanofi's schedule.
- S & P 500 ends higher as traders shift from AI to healthcare
The S&P 500 closed up 0.33% at 7,744.06 points after early losses, as investors moved from AI stocks into healthcare and consumer names such as Eli Lilly, UnitedHealth and Walmart. Dell Technologies and Hewlett Packard Enterprise fell 6.9% and 7.1% on worries about AI firms facing higher borrowing costs. The Nasdaq rose 0.08% to 26,713.03 points and the Dow gained 1.08% to 52,177.69 points. US producer prices rose by the most in years, and traders priced a 67% chance of a Fed rate hike by December, up from 62% on Wednesday. Rocket Lab fell 6.6% after delaying its Neutron rocket launch, and FMC plunged over 30% after cutting its third-quarter outlook.
- US stocks : Dow , S & P 500 end higher as traders shift from AI to healthcare
Related markets
Latest news
- Tether: Senator's investigation misses positive work that's led to lower Iran volumes
Tether CEO Paolo Ardoino says a recent Senate Democrats report, led by Senator Richard Blumenthal, missed the company's work to enforce sanctions. He claims Tether froze suspicious addresses on average 4 weeks before OFAC and NBCTF sanction designations, and before Chainalysis labelled them in 99% of cases since 2023. Ardoino says these actions led to Iran-linked stablecoin volumes declining by 94%. The Senate report, which described Tether as providing a significant financial lifeline within Iran's shadow banking network, said the company did not comprehensively freeze flagged wallets before 2024. Blumenthal is also probing Tether's relationship with its U.S. financial partner, Cantor Fitzgerald.
- Sandisk, Datadog, Amazon Lead S&P 500 As AI Stocks Rebound
Western Digital, Sandisk, Datadog, Twilio and Amazon led the S&P 500 on Monday as AI-related stocks rebounded. Western Digital (WDC) rose 6.1% to 352.21, still below all its key moving averages, after plunging 16.4% last week. The hard-drive maker reports fiscal Q1 results late Thursday, kicking off a round of earnings for memory-related companies.
- Tesla Rises on a Foundry Agreement With Intel as JPMorgan Upgrades the Stock
Intel shares rose 4% and Tesla rose 3% after JPMorgan upgraded Intel to Neutral from Underweight and kept its $85 price target. Tesla committed to Intel's 14A process in April, and JPMorgan credits CEO Lip-Bu Tan's execution, expects positive EPS revisions, and sees its 2028 EPS estimate about 15% above consensus. The upgrade remains cautious: Intel is down about 36% from its June peak, its share of server CPU revenue has fallen from 77% to 53% since 2022, and its outside foundry business brought in barely $1 billion of annualized revenue in the first half of 2026. Intel's capital spending has exceeded operating cash every year since 2022, so the $20 billion stock sale and an anchor customer make the factory plan more fundable, though 14A won't reach high-volume production until 2028 and neither company has disclosed the deal's value. Intel reports third-quarter results on Oct. 29.
- What Crypto Bear Market? All of These Cryptocurrencies Have Skyrocketed in Value This Year
Bitcoin is down nearly 10% year-to-date, Ethereum is down 20% and XRP is down 30%, but several altcoins have risen sharply in 2026. Hyperliquid (HYPE) is up 210% for the year with a market cap of $20 billion, helped by the launch of spot ETFs, and Zcash (ZEC) is up 128%, with Grayscale's spot Zcash ETF attracting more than $500 million in under 30 days. NEAR Protocol, repositioned for the AI agent economy, is up 240% in 2026 but still down 75% from its January 2022 all-time high. Venice Token (VVV) is up 1,300% this year with a market cap just above $1 billion. The author favors Hyperliquid, citing its popularity overseas, the recent opening of the U.S. market to perpetual futures, and implicit support from the Trump administration.
- Nscale in talks for $45 billion Anthropic AI deal as IPO looms
Nscale is in talks to secure a computing deal worth about $45 billion with Anthropic, according to Bloomberg News, which could strengthen the Nvidia-backed data center developer's bid for a roughly $30 billion valuation in its planned IPO. The proposed agreement would cover a second building at Nscale's Monarch campus in West Virginia, delivering 460 megawatts of capacity powered by Nvidia's Vera Rubin chips, and could be finalized within days, though terms could still change. Anthropic already has infrastructure agreements with Nscale worth as much as $44.6 billion, according to Nscale's IPO filing, and holds a right of first refusal on the campus's anticipated third building. Investors are scrutinizing AI infrastructure economics, and Nscale faces questions similar to CoreWeave's about financing, execution and converting its backlog into cash flow, since its contracts are future commitments rather than collected cash. Representatives for Nscale and Anthropic declined to comment.
- A bad case of when your crypto thesis is based on one guy
Turkey confirmed the arrest of Hex founder Richard Hart, who was detained in Istanbul on October 14, and said police seized 7.15 million cash, six cold wallets, 28 watches, 300 bags and seven firearms during searches across 15 addresses. The detention relates to a Finnish Interpol red notice over suspicions of gross tax evasion and assault in Finland. Hart had an SCC civil case dismissed in 2025 on jurisdictional grounds, and the SCC declined to refile it. The speaker argues that investors who buy the token based on one founder face a sharp price drop if that person runs into legal trouble, and advises against investing just because of a founder.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.